| Detected | Trial | Change |
|---|---|---|
| 2026-07-31 | NCT05973773 REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) |
date change Primary completion pushed: 2026-10-29 -> 2027-05-27 |
| 2026-07-29 | NCT06506955 Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy… |
overall status: Enrolling by Invitation → Active, Not Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07128199 | A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant… | NSCLC, Stage IB-IIIA | Active, Not Recruiting |
| NCT05973773 | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone… | Myelodysplastic Syndromes | Recruiting |
| NCT06506955 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy… | Advanced/Metastatic Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05967689 | A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With… | Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | Recruiting |
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or… | Advanced Cholangiocarcinoma | Recruiting |
| NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid… | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Active, Not Recruiting |
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard… | Acute Myeloid Leukemia | Enrolling by Invitation |
| Phase 1/2 | |||
| NCT04657081 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute… | Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Solid Tumors | Active, Not Recruiting |
| Phase 1 | |||
| NCT04953897 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in… | Acute Myeloid Leukemia | Recruiting |
| NCT04953910 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in… | Acute Myeloid Leukemia | Recruiting |
| NCT07691606 | A Study of ARC-02 in B-cell NHL | B-cell Non Hodgkin Lymphoma | Recruiting |